Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients

International Journal of Antimicrobial Agents

Volumn 48, Issue 5, 2016, Pages 492-497

  Tsioutis, Constantinos ^a   Kritsotakis, Evangelos I ^b   Karageorgos, Spyridon A ^a   Stratakou, Soultana ^a   Psarologakis, Charalambos ^a   Kokkini, Sofia ^a   Gikas, Achilleas ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Acinetobacter; Antimicrobial resistance; Colistin; Extensively drug resistant; Treatment; Ventilator associated pneumonia

Indexed keywords

COLISTIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM ISOLATE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; GREECE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER BAUMANNII; ADOLESCENT; COMBINATION DRUG THERAPY; CRITICAL ILLNESS; DRUG EFFECTS; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTIDRUG RESISTANCE; PATHOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED; PROCEDURES; SURVIVAL ANALYSIS; UNIVERSITY HOSPITAL; VERY ELDERLY; YOUNG ADULT;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; GREECE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84994008658     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.07.007     Document Type: Article

References (35)

1. [1] Waters, B., Muscedere, J., A 2015 update on ventilator-associated pneumonia: new insights on its prevention, diagnosis, and treatment. Curr Infect Dis Rep, 17, 2015, 496.
2. [2] Kempf, M., Rolain, J.-M., Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 39 (2012), 105–114.
3. [3] Tacconelli, E., Cataldo, M.A., Dancer, S.J., De Angelis, G., Falcone, M., Frank, U., et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 20 (2014), 1–55.
4. [4] Magiorakos, A.-P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
5. [5] Poulikakos, P., Tansarli, G.S., Falagas, M.E., Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis 33 (2014), 1675–1685.
6. [6] Dimopoulos, G., Koulenti, D., Tabah, A., Poulakou, G., Vesin, A., Arvaniti, K., et al. Bloodstream infections in ICU with increased resistance: epidemiology and outcomes. Minerva Anestesiol 81 (2015), 405–418.
7. [7] Khawcharoenporn, T., Pruetpongpun, N., Tiamsak, P., Rutchanawech, S., Mundy, L.M., Apisarnthanarak, A., Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents 43 (2014), 378–382.
8. [8] Daikos, G.L., Tsaousi, S., Tzouvelekis, L.S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58 (2014), 2322–2328.
9. [9] Paul, M., Carmeli, Y., Durante-Mangoni, E., Mouton, J.W., Tacconelli, E., Theuretzbacher, U., et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69 (2014), 2305–2309.
10. [10] Von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gøtzsche, P.C., Vandenbroucke, J.P., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12 (2014), 1495–1499.
11. [11] Horan, T.C., Andrus, M., Dudeck, M.A., CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36 (2008), 309–332.
12. [12] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. Document M100-S17, 2007, CLSI, Wayne, PA.
13. [13] Wyeth Pharmaceuticals Inc, Tygacil package insert. 2005, Wyeth Pharmaceuticals Inc.
14. [14] Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
15. [15] McCabe, W.R., Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med, 110, 1962, 847.
16. [16] Knaus, W.A., Draper, E.A., Wagner, D.P., Zimmerman, J.E., APACHE II: a severity of disease classification system. Crit Care Med 13 (1985), 818–829.
17. [17] Gilbert, N., Moellering, R., Eliopoulos, G., Chambers, H., Saag, S., (eds.) The Sanford guide to antimicrobial therapy, 42nd ed, 2012, Antimicrobial Therapy, Inc., Sperryville, VA.
18. [18] Dunkler, D., Plischke, M., Leffondré, K., Heinze, G., Augmented backward elimination: a pragmatic and purposeful way to develop statistical models. PLoS ONE, 9, 2014, e113677.
19. [19] Özgür, E.S., Horasan, E.S., Karaca, K., Ersöz, G., Naycı Atış, S., Kaya, A., Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. Am J Infect Control 42 (2014), 206–208.
20. [20] Inchai, J., Liwsrisakun, C., Theerakittikul, T., Chaiwarith, R., Khositsakulchai, W., Pothirat, C., Risk factors of multidrug-resistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a medical intensive care unit of university hospital in Thailand. J Infect Chemother 21 (2015), 570–574.
21. [21] Aydemir, H., Akduman, D., Piskin, N., Comert, F., Horuz, E., Terzi, A., et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 141 (2013), 1214–1222.
22. [22] Batirel, A., Balkan, I.I., Karabay, O., Agalar, C., Akalin, S., Alici, O., et al. Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 33 (2014), 1311–1322.
23. [23] Shields, R.K., Clancy, C.J., Gillis, L.M., Kwak, E.J., Silveira, F.P., Massih, R.C.A., et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS ONE, 7, 2012, e52349.
24. [24] Durante-Mangoni, E., Signoriello, G., Andini, R., Mattei, A., De Cristoforo, M., Murino, P., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57 (2013), 349–358.
25. [25] Garnacho-Montero, J., Ortiz-Leyba, C., Jiménez-Jiménez, F.J., Barrero-Almodóvar, A.E., García-Garmendia, J.L., Bernabeu-Wittell, M., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36 (2003), 1111–1118.
26. [26] Garnacho-Montero, J., Corcia-Palomo, Y., Amaya-Villar, R., Martin-Villen, L., How to treat VAP due to MDR pathogens in ICU patients. BMC Infect Dis, 14, 2014, 135.
27. [27] American Thoracic Society; Infectious Diseases Society of America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005), 388–416.
28. [28] Karaiskos, I., Giamarellou, H., Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15 (2014), 1351–1370.
29. [29] Sun, Y., Cai, Y., Liu, X., Bai, N., Liang, B., Wang, R., The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 41 (2013), 110–116.
30. [30] Chan, J.D., Graves, J.A., Dellit, T.H., Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 25 (2010), 343–348.
31. [31] Chan, M.-C., Chiu, S.-K., Hsueh, P.-R., Wang, N.-C., Wang, C.-C., Fang, C.-T., Risk factors for healthcare-associated extensively drug-resistant Acinetobacter baumannii infections: a case–control study. PLoS ONE, 9, 2014, e85973.
32. [32] Kritsotakis, E.I., Tsioutis, C., Roumbelaki, M., Christidou, A., Gikas, A., Antibiotic use and the risk of carbapenem-resistant extended-spectrum-β-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case–control study. J Antimicrob Chemother 66 (2011), 1383–1391.
33. [33] Stevens, J.P., Kachniarz, B., Wright, S.B., Gillis, J., Talmor, D., Clardy, P., et al. When policy gets it right: variability in U.S. hospitals’ diagnosis of ventilator-associated pneumonia. Crit Care Med 42 (2014), 497–503.
34. [34] Klouwenberg, P.M.C.K., Ong, D.S.Y., Bos, L.D.J., de Beer, F.M., van Hooijdonk, R.T.M., Huson, M.A., et al. Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. Crit Care Med 41 (2013), 2373–2378.
35. [35] Boots, R.J., Lipman, J., Bellomo, R., Stephens, D., Heller, R.F., Predictors of physician confidence to diagnose pneumonia and determine illness severity in ventilated patients. Australian and New Zealand Practice in Intensive Care (ANZPIC II). Anaesth Intensive Care, 33, 2005, 112.